Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLK-301 for Dry Eye Disease
NCT05119920Phase 2Completed
- Sponsor
- Glaukos Corporation
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GLK-301 in dry eye disease (DED), sponsored by Glaukos Corporation. Started Jan 2022; status: completed.
02
Drugs
GLK-301
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05119920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119920.